3 Reasons Investors Are Scared of Biotech Stocks

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Biotechs offer the possibility of monster returns. Overnight doubles aren't out of the question. Triples and quadruples as a drug successfully progresses through the clinical trial process are the norm.

And yet many investors shy away from the industry. Let's take a look at why.

Down on bad news
Biotechs face many succeed-or-fail binary events over the course of drug development. Clinical trials, Food and Drug Administration advisory committee meetings, and FDA approval decisions all offer an opportunity for a monster pop or a monster drop.

As drugs succeed, they're given a larger value, but that means if a drug subsequently fails, it has a larger effect on the stock price. Phase 1 failures tend to have very little effect on stock prices. Phase 2 hurts a little more, especially for companies with limited pipelines. Drugs that fail in phase 3 are quite costly.

For example, shares of ZIOPHARM Oncology (NASDAQ: ZIOP  ) were cut by two-thirds this week after its cancer drug palifosfamide failed a phase 3 trial in metastatic soft tissue sarcoma. The smaller phase 2 trial suggested the drug was working, which built up the value of the company. The drug did delay tumor progression by a month, but the increase wasn't statistically significant.

Down on good news
These days, it doesn't take bad news to send shares down. Good-but-expected news is often enough to do it. After the excitement of the binary event is over, investors flee. It's "sell the news" without the "buy the rumor."

For example, Navidea Biopharmaceuticals  (NYSEMKT: NAVB  ) dropped 12% following the approval of its lymph node diagnostic Lymphoseek this month. The approval was widely expected after an earlier FDA rejection for issues at a third-party manufacturer.

In December, ARIAD Pharmaceuticals (NASDAQ: ARIA  ) experienced the same issue with a double-digit drop after its leukemia drug Iclusig was approved by the FDA. Strong data and a fast-track designation got the drug approved quickly.

Down on unexpected news
The worst risk is the kind that can't be foreseen.

At least with binary events, investors can see it coming. Data from a clinical trial will be released. The FDA will make a decision about whether the drug is approvable. The exact date might not be known, but at least it can be pinpointed to a month or two, with many events coming in a smaller window than that.

But sometimes events come out of left field. And they're almost never the good kind.

Shares of Affymax  (NASDAQOTH: AFFY  ) , for instance, are down more than 90% year to date after the company had to recall all of its red blood cell stimulating drug, Omontys, that treats patients on dialysis with chronic kidney disease. The drug caused allergic reaction in some patients, which was occasionally fatal.

Didn't you say something about monster returns?
I did.

While there's a lot of risk investing in the biotech industry, there's also the potential for insane increases in share prices. Regeneron Pharmaceuticals (NASDAQ: REGN  ) , for instance is up 550% over the last 3 years thanks to the successful development and launch of its macular degeneration drug Eylea.

So how do you find the next Regeneron while avoiding companies like ZIOPHARM, Navidea, ARIAD, and Affymax? A little skill and a little luck.

Binary decisions that look like they're a shoo-in typically don't result in big returns; investors have already factored in the approval or positive clinical trial and sell after the news is released. When the result is negative, like it was for ZIOPHARM, it's even more costly.

Investing in less-than-sure-things is more risky, but it comes with much larger rewards. The trick is to find companies where other investors are discounting the risk more than is necessary, which allows you to buy with a margin of safety.

It's hard to predict a drug getting pulled off the market like Omontys was. Instead, investors have to make sure the potential return from a company with a drug already on the market justifies the risk. A commercial-stage drugmaker really has to be a bargain to justify the risk, especially given the lackluster launches recently.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3477184, ~/Articles/ArticleHandler.aspx, 5/24/2016 1:43:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 17,701.30 208.37 1.19%
S&P 500 2,075.41 27.37 1.34%
NASD 4,854.37 88.59 1.86%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2016 10:42 AM
AFFY $0.08 Down +0.00 -1.79%
Affymax, Inc. CAPS Rating: *
ARIA $8.05 Down -0.03 -0.37%
Ariad Pharmaceutic… CAPS Rating: **
NAVB $0.86 Down -0.02 -2.20%
Navidea Biopharmac… CAPS Rating: *
REGN $396.82 Up +4.18 +1.06%
Regeneron Pharmace… CAPS Rating: ***
ZIOP $6.97 Up +0.01 +0.14%
ZIOPHARM Oncology CAPS Rating: **